

Felicita Andreotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3092758/publications.pdf>

Version: 2024-02-01

214
papers

40,982
citations

17405

63
h-index

2375

198
g-index

229
all docs

229
docs citations

229
times ranked

32719
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 519-528.	1.4	13
2	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 677-686.	1.4	45
3	Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. <i>Drugs - Real World Outcomes</i> , 2022, 9, 199-209.	0.7	11
4	Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study. <i>Metabolites</i> , 2022, 12, 123.	1.3	5
5	Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS. <i>European Heart Journal</i> , 2022, 43, 2798-2800.	1.0	5
6	Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 86-93.	1.4	34
7	From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19. <i>International Journal of Cardiology</i> , 2021, 326, 243-247.	0.8	14
8	Safety and efficacy of P2Y ₁₂ inhibitor monotherapy in patients undergoing percutaneous coronary interventions. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 9-21.	1.0	18
9	Methodological education in response to the quality of COVID-19 publications. <i>Pharmacological Research</i> , 2021, 164, 105381.	3.1	2
10	Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 285-289.	0.5	16
11	Doppler Ultrasound Monitoring of Echogenicity in Asymptomatic Subcritical Carotid Stenosis and Assessment of Response to Oral Supplementation of Vitamin K2 (PLAK2 Randomized Controlled Trial). <i>Diagnostics</i> , 2021, 11, 229.	1.3	2
12	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2021, 143, 673-684.	1.6	10
13	Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13551.	1.7	8
14	Sex- and gender-specific precision medicine for chronic coronary syndromes: challenges and opportunities. <i>Kardiologia Polska</i> , 2021, 79, 373-375.	0.3	2
15	Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 1755.	1.0	1
16	Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management. <i>European Cardiology Review</i> , 2021, 16, e23.	0.7	14
17	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021, 42, 4638-4651.	1.0	80
18	Family history in first degree relatives of patients with premature cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 333, 215-218.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Development and Validation of a Practical Model to Identify Patients at Risk of Bleeding After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1196-1206.	1.1	24
20	When a meta-analysis equals a single large-scale trial with meaningful follow-up. <i>European Heart Journal</i> , 2021, 42, 3884-3885.	1.0	3
21	Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention?. <i>European Heart Journal</i> , 2021, 42, 3187-3189.	1.0	3
22	Metabolomic correlates of coronary atherosclerosis, cardiovascular risk, both or neither. Results of the 2 Å– 2 phenotypic CAPIRE study. <i>International Journal of Cardiology</i> , 2021, 336, 14-21.	0.8	9
23	Closing the Gap Between Populations Enrolled in Traditional Randomized Controlled Trials and Patients Encountered in Clinical Practice: The Case of Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008840.	1.6	3
24	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. <i>International Journal of Cardiology</i> , 2021, 337, 1-8.	0.8	6
25	Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111783.	2.5	0
26	Unexpected high mortality associated with very low lipoprotein(a) after acute myocardial infarction: Identifying the unknown. <i>European Journal of Internal Medicine</i> , 2021, 91, 26-28.	1.0	0
27	Efficacy of COVID-19 Vaccines Against Active Comparators or Inert Placebos. <i>JAMA Internal Medicine</i> , 2021, 181, 1257.	2.6	1
28	Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromes. <i>European Heart Journal</i> , 2021, 42, 4699-4700.	1.0	4
29	Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110263.	1.1	5
30	ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrial fibrillation: the (ORIGAMI) study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 175-179.	0.6	3
31	Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine. <i>European Heart Journal Supplements</i> , 2021, 23, E13-E18.	0.0	10
32	Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: not a matter of faith. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e16-e17.	1.4	2
33	Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 128-129.	1.4	19
34	Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 43-56.	1.4	26
35	Aspirin in primary prevention of cardiovascular disease in the elderly. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 326-327.	1.4	2
36	Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people. <i>American Heart Journal</i> , 2020, 220, 12-19.	1.2	37

#	ARTICLE	IF	CITATIONS
37	COVID-19 trials in Italy: A call for simplicity, top standards and global pooling. International Journal of Cardiology, 2020, 318, 160-164.	0.8	5
38	Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog. Journal of Cardiovascular Medicine, 2020, 21, 841-844.	0.6	5
39	Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. IJC Heart and Vasculature, 2020, 28, 100524.	0.6	13
40	Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace, 2020, 22, 538-546.	0.7	36
41	Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. Diabetes Care, 2020, 43, 843-851.	4.3	34
42	Stent Thrombosis With Dual Antithrombotic Therapy in Atrial Fibrillation ACS/PCI Trials. Journal of the American College of Cardiology, 2020, 75, 1727-1728.	1.2	8
43	Cancer unmasked by bleeding during anticoagulant therapy: when a problem may become an opportunity. European Heart Journal, 2020, , .	1.0	1
44	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	1.0	4,537
45	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	0.6	402
46	Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort?. European Heart Journal, 2019, 40, 3602-3604.	1.0	3
47	In reply "Real World TAVR: Data in Constant Flux. Mayo Clinic Proceedings, 2019, 94, 1643-1644.	1.4	0
48	Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. ESC Heart Failure, 2019, 6, 884-888.	1.4	5
49	Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry. Mayo Clinic Proceedings, 2019, 94, 1457-1466.	1.4	19
50	Diagnoses and outcomes in patients with suspected angina: what are they trying to tell us?. European Heart Journal, 2019, 40, 1436-1439.	1.0	1
51	Early anticoagulation in the current management of NSTEMI-ACS: Evidence, guidelines, practice and perspectives. International Journal of Cardiology, 2019, 275, 39-45.	0.8	12
52	Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 55-56.	1.4	6
53	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nature Reviews Cardiology, 2019, 16, 113-130.	6.1	73
54	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 47-54.	1.4	16

#	ARTICLE	IF	CITATIONS
55	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	1.0	106
56	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1566.	3.8	339
57	Prolonged endogenous fibrinolysis predicts reduced survival after acute coronary syndromes. <i>European Heart Journal</i> , 2018, 39, 1086-1088.	1.0	4
58	Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2018, 258, 59-67.	0.8	14
59	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	1.0	2,246
60	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	0.6	261
61	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. <i>Annals of Internal Medicine</i> , 2018, 168, 234.	2.0	2
62	Meta-analysis of LDL-C Lowering and Mortality—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1493.	3.8	0
63	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017, 38, ehw159.	1.0	53
64	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454.	1.0	86
65	Survival Benefits of Invasive Versus Conservative Strategies in Heart Failure in Patients With Reduced Ejection Fraction and Coronary Artery Disease. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	123
66	Anemia contributes to cardiovascular disease through reductions in nitric oxide. <i>Journal of Applied Physiology</i> , 2017, 122, 414-417.	1.2	7
67	Aspirin and the prevention of a common disease: Colorectal cancer. <i>International Journal of Cardiology</i> , 2017, 248, 394-395.	0.8	9
68	Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel. <i>International Journal of Cardiology</i> , 2017, 249, 249-256.	0.8	12
69	Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism. <i>Data in Brief</i> , 2017, 15, 532-539.	0.5	1
70	Last Word on Viewpoint: Anemia contributes to cardiovascular disease through reductions in nitric oxide. <i>Journal of Applied Physiology</i> , 2017, 122, 420-421.	1.2	0
71	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. <i>Annals of Internal Medicine</i> , 2017, 167, 103.	2.0	43
72	Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures—a systematic review and network meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0168726.	1.1	25

#	ARTICLE	IF	CITATIONS
73	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2016, 115, 685-711.	1.8	24
74	Clinical Perspectives and Pearls from the 2015 ESC NSTEMI-ACS Guidelines. <i>Current Cardiology Reports</i> , 2016, 18, 48.	1.3	4
75	Stakeholders in NOACs prescription: authors' reply. <i>Europace</i> , 2016, 18, 788.2-789.	0.7	2
76	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
77	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1125.	0.4	57
78	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2015, 114, 933-944.	1.8	11
79	Sex differences in mechanisms, presentation and management of ischaemic heart disease. <i>Atherosclerosis</i> , 2015, 241, 157-168.	0.4	113
80	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304.	1.0	175
81	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. <i>Europace</i> , 2015, 17, 1007-1017.	0.7	46
82	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2015, 350, h1618-h1618.	3.0	279
83	Comprehensive Meta-Analysis of Safety and Efficacy of Bivalirudin Versus Heparin With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 201-213.	1.1	69
84	Female sex as an independent risk factor for stroke in atrial fibrillation: Possible mechanisms. <i>Thrombosis and Haemostasis</i> , 2014, 111, 385-391.	1.8	90
85	Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-782.	1.8	142
86	Meta-Analysis of Time-Related Benefits of Statin Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1753-1764.	0.7	80
87	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A –state-of-the-art– paper. <i>European Heart Journal</i> , 2014, 35, 2213-2223.	1.0	78
88	Aspirin Therapy in Primary Cardiovascular Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 319-327.	1.2	150
89	Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2013, 158, 261.	2.0	151
90	Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. <i>Clinical Research in Cardiology</i> , 2013, 102, 279-287.	1.5	29

#	ARTICLE	IF	CITATIONS
91	Antithrombotic Therapy for Patients With Atrial Fibrillation and Atherothrombotic Vascular Disease. <i>Circulation</i> , 2013, 128, 684-686.	1.6	6
92	Leading Avoidable Cause of Premature Deaths Worldwide: Case for Obesity. <i>American Journal of Medicine</i> , 2013, 126, 97-98.	0.6	46
93	Defining the Role of Left Atrial Appendage Closure in Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 79-82.	0.4	2
94	Definición del papel de la oclusión de la orejuela auricular izquierda en la fibrilación auricular. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 79-82.	0.6	6
95	Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2013, 111, 1123-1130.	0.7	239
96	General mechanisms of coagulation and targets of anticoagulants (Section I). <i>Thrombosis and Haemostasis</i> , 2013, 109, 569-579.	1.8	165
97	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	1.0	3,915
98	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ, The</i> , 2013, 347, f6530-f6530.	3.0	194
99	Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). <i>Thrombosis and Haemostasis</i> , 2013, 109, 769-786.	1.8	154
100	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107.	1.8	347
101	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012, 14, 681-695.	2.9	71
102	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1009-1022.	1.8	65
103	Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: A meta-analysis of randomized trials. <i>Atherosclerosis</i> , 2012, 222, 1-7.	0.4	36
104	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012, 33, 2451-2496.	1.0	3,465
105	Guidelines on the management of valvular heart disease (version 2012). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S1-S44.	0.6	1,313
106	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1413-1425.	1.2	257
107	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	1.0	993
108	Diurnal variation in platelet inhibition by clopidogrel. <i>Platelets</i> , 2011, 22, 579-587.	1.1	52

#	ARTICLE	IF	CITATIONS
109	Polycythemia, vascular function, and hemoglobin-nitric oxide reactions. <i>Journal of Applied Physiology</i> , 2011, 111, 331-331.	1.2	2
110	Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011..	1.8	234
111	Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1210-1219.	1.7	13
112	Hemoglobin Levels, Nitric Oxide Bioavailability and Cardiovascular Outcomes. <i>American Journal of Cardiology</i> , 2011, 107, 1099.	0.7	1
113	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	1.0	203
114	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	1.0	343
115	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746.	0.7	197
116	Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2011, 7, 985-994.	1.4	87
117	Testosterone, tissue factor inhibition and vascular aging. <i>Thrombosis and Haemostasis</i> , 2010, 103, 9-10.	1.8	3
118	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	1.0	1,392
119	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2010, 31, 1311-1318.	1.0	216
120	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. <i>Thrombosis and Haemostasis</i> , 2010, 103, 13-28.	1.8	292
121	New Anticoagulants and the Future of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 1223-1229.	0.4	5
122	Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2010, 145, 230-232.	0.8	7
123	Genetics and Genomics in the Management of Hemostasis and Thrombosis. , 2010, , 374-389.		0
124	The unstable plaque: a broken balance. <i>European Heart Journal</i> , 2009, 30, 1821-1823.	1.0	6
125	Asymmetric dimethylarginine and impaired cardiovascular healing. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 168-171.	1.0	4
126	Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 166-172.	1.0	5

#	ARTICLE	IF	CITATIONS
127	Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPÄMINONDAS). Journal of Thrombosis and Thrombolysis, 2009, 28, 489-495.	1.0	25
128	Role of PAPP-A in atherothrombosis: Messages to take home. Atherosclerosis, 2009, 203, 353-354.	0.4	9
129	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Heart Journal, 2009, 30, 2769-2812.	1.0	735
130	Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the "OPTIMIZE-IT"™ pilot randomized study. Journal of Cardiovascular Medicine, 2009, 10, 245-251.	0.6	18
131	Predictors of exercise-induced platelet reactivity in patients with chronic stable angina. Journal of Cardiovascular Medicine, 2009, 10, 891-897.	0.6	7
132	Hemostasis and Thrombosis. , 2009, , 755-772.		0
133	Erythropoietin in heart and vessels: focus on transcription and signalling pathways. Journal of Thrombosis and Thrombolysis, 2008, 26, 183-187.	1.0	72
134	Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2008, 29, 2276-2315.	1.0	2,645
135	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. European Heart Journal, 2008, 29, 2909-2945.	1.0	2,128
136	Women and coronary disease. Heart, 2008, 94, 108-116.	1.2	55
137	Hypercoagulable States in Cardiovascular Disease. Circulation, 2008, 118, 2286-2297.	1.6	110
138	Body fat and cardiovascular risk: understanding the obesity paradox. European Heart Journal, 2008, 30, 752-754.	1.0	32
139	Intraventricular conduction abnormalities in young patients with type 1 diabetes mellitus. Journal of Cardiovascular Medicine, 2008, 9, 714-715.	0.6	0
140	Expanding the role of coagulation in arterial thrombosis: Evidence from animal models using a new factor Xa inhibitor. Thrombosis and Haemostasis, 2008, 99, 651-652.	1.8	1
141	Letter by Andreotti et al Regarding Article, "Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study" Circulation, 2007, 115, e313; author reply e314.	1.6	2
142	IgA anticardiolipin antibody is associated with the extent of daily-life ischaemia in patients with chronic coronary artery disease. Heart, 2007, 93, 1412-1413.	1.2	1
143	Contrast-induced nephropathy and mortality: possible crucial role of asymmetric dimethylarginine. Journal of Cardiovascular Medicine, 2007, 8, 1043.	0.6	1
144	Adjusted Indirect Meta-Analysis of Aspirin Plus Warfarin at International Normalized Ratios 2 to 3 Versus Aspirin Plus Clopidogrel After Acute Coronary Syndromes. American Journal of Cardiology, 2007, 99, 1637-1642.	0.7	45

#	ARTICLE	IF	CITATIONS
145	Reduced CD34+, renal anemia, and adverse outcomes. American Heart Journal, 2006, 152, e21.	1.2	5
146	Preteomics, metabolomics and progenitor cells in acute coronary syndromes. Journal of Thrombosis and Thrombolysis, 2006, 22, 85-88.	1.0	7
147	Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25â€¦307 patients. European Heart Journal, 2006, 27, 519-526.	1.0	263
148	Pregnancy associated plasma protein-A and coronary atherosclerosis: marker, friend, or foe?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 2075-2076.	1.0	35
149	Interplay of platelet polymorphisms, risk factors, and Von Willebrand factor, and flow-mediated conditions in determining collagenâ€™adenosine diphosphate PFA-100 results in patients with coronary artery disease. Blood Coagulation and Fibrinolysis, 2005, 16, 97-104.	0.5	6
150	Atherothrombotic Disorders. Circulation, 2005, 111, 1855-1863.	1.6	48
151	Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. European Heart Journal, 2005, 26, 2000-2006.	1.0	120
152	Relation between nitric oxide metabolites and haemoglobin concentrations in patients with ischaemic heart disease. Heart, 2005, 93, 255-257.	1.2	7
153	Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. European Heart Journal, 2005, 26, 1196-1204.	1.0	235
154	Substandard life-saving drugs: a global concern. European Heart Journal, 2005, 26, 858-860.	1.0	0
155	Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. European Heart Journal, 2005, 26, 1618-1624.	1.0	40
156	Inflammation, genetics, and ischemic heart disease: focus on the major histocompatibility complex (MHC) genes. Cytokine, 2005, 29, 187-196.	1.4	17
157	Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease. American Heart Journal, 2005, 149, 832-839.	1.2	65
158	Pregnancy-Associated Plasma Protein-A and Acute Coronary Syndromes: Cause or Consequence?. Journal of the American College of Cardiology, 2005, 46, 1583-1584.	1.2	13
159	Heart-Kidney Interactions in Ischemic Syndromes. Circulation, 2004, 109, e31-2; author reply e31-2.	1.6	48
160	Pregnancy-Associated Plasma Protein A as Predictor of Outcome in Patients With Suspected Acute Coronary Syndromes. Circulation, 2004, 109, e211-2; author reply e211-2.	1.6	25
161	Insulin-Like Growth Factor-1 as a Vascular Protective Factor. Circulation, 2004, 110, 2260-2265.	1.6	231
162	Favorable cardiac risk among elderly breast carcinoma survivors. Cancer, 2004, 100, 878-879.	2.0	4

#	ARTICLE	IF	CITATIONS
163	Antibiotic therapy for severe bacterial infections: correlation between the inhibitory quotient and outcome. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 120-128.	1.1	13
164	4G/5G PAI-1 Promoter Polymorphism and Acute-Phase Levels of PAI-1 Following Coronary Bypass Surgery: A Prospective Study. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 16, 149-154.	1.0	22
165	Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 126, 1107-1112.	0.4	66
166	Relation Between Platelet Response to Exercise and Coronary Angiographic Findings in Patients With Effort Angina. <i>Circulation</i> , 2003, 107, 1378-1382.	1.6	54
167	The -174G/C Interleukin-6 Polymorphism Influences Postoperative Interleukin-6 Levels and Postoperative Atrial Fibrillation. Is Atrial Fibrillation an Inflammatory Complication?. <i>Circulation</i> , 2003, 108, 195II-199.	1.6	264
168	IGF-1 and Macrovascular Complications of Diabetes: Alternative interpretations of recently published data. <i>Diabetes Care</i> , 2003, 26, 1653-1654.	4.3	17
169	Increased Platelet Reactivity Due to Platelet Receptor Polymorphisms? Not in the Real World. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1703-1704.	1.1	0
170	The strengths and frailties of women with cardiovascular disease. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003, 4, 361-2.	0.1	0
171	Sex, survival bias, and mortality following acute myocardial infarction. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003, 4, 508-10.	0.1	3
172	Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. <i>British Heart Journal</i> , 2002, 87, 107-112.	2.2	133
173	Preoperative C-reactive protein level and outcome following coronary surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2002, 22, 521-526.	0.6	44
174	Potential of Fibrinolytic Therapy in Acute Myocardial Infarction: Expanding the Role of ACE-Inhibitors. <i>Thrombosis and Haemostasis</i> , 2002, 88, 176-178.	1.8	8
175	Normothermia does not improve postoperative hemostasis nor does it reduce inflammatory activation in patients undergoing primary isolated coronary artery bypass. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2002, 123, 1092-1100.	0.4	28
176	Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. <i>American Journal of Cardiology</i> , 2002, 89, 973-975.	0.7	49
177	Prothrombotic response to coronary angioplasty in patients with unstable angina and raised C-reactive protein. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 131-138.	1.0	8
178	Potential of fibrinolytic therapy in acute myocardial infarction: expanding the role of ACE-inhibitors. <i>Thrombosis and Haemostasis</i> , 2002, 88, 176-8.	1.8	3
179	Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001, 38, 26-32.	1.2	94
180	Coronary Artero-Venous Gradient of Endogenous Urokinase. <i>Thrombosis Research</i> , 2001, 103, S29-S34.	0.8	0

#	ARTICLE	IF	CITATIONS
181	The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. <i>British Journal of Haematology</i> , 2001, 114, 150-154.	1.2	24
182	Low-grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia. <i>American Journal of Cardiology</i> , 2001, 87, 16-20.	0.7	46
183	Relation of the ~ 174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. <i>American Journal of Cardiology</i> , 2001, 88, 1125-1128.	0.7	161
184	Key references: Basic fibrinolysis and thrombolysis selected references: 1987-1997. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 61-68.	1.0	0
185	Homocysteine and risk of cardiovascular disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 13-21.	1.0	35
186	Ticlopidine and aspirin fail to suppress the increased platelet aggregability that follows percutaneous coronary interventions. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 265-269.	1.0	12
187	G20210A Prothrombin Gene Polymorphism and Extent of Coronary Disease. <i>Thrombosis and Haemostasis</i> , 2000, 84, 142-143.	1.8	6
188	The G20210A Prothrombin Mutation and the Physicians' Health Study. <i>Circulation</i> , 2000, 101, E207-8.	1.6	7
189	Intracranial haemorrhage with bolus thrombolytic agents. <i>Lancet, The</i> , 2000, 356, 1849-1850.	6.3	5
190	Increased Proinflammatory Cytokines in Patients With Chronic Stable Angina and Their Reduction By Aspirin. <i>Circulation</i> , 1999, 100, 793-798.	1.6	541
191	Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects. <i>Journal of Thrombosis and Thrombolysis</i> , 1999, 8, 207-212.	1.0	9
192	Comparison of insulin response to intravenous glucose in healed myocardial infarction, in cooled-off unstable and stable angina pectoris, and in healthy subjects. <i>American Journal of Cardiology</i> , 1999, 84, 870-875.	0.7	1
193	Preinfarction Angina and Improved Reperfusion of the Infarct-related Artery. <i>Thrombosis and Haemostasis</i> , 1999, 82, 68-72.	1.8	8
194	Platelet and Thrombin Activity Following Cardiac Catheterization Despite Treatment with Aspirin. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 6, 141-145.	1.0	3
195	Ischaemic preconditioning. <i>Lancet, The</i> , 1996, 348, 204.	6.3	13
196	Different effects of lipopolysaccharide on plasminogen activator inhibitor-1 production in aortic media in vivo and in culture. <i>Journal of Thrombosis and Thrombolysis</i> , 1996, 3, 215-223.	1.0	1
197	Preinfarction Angina as a Predictor of More Rapid Coronary Thrombolysis in Patients with Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 1996, 334, 7-12.	13.9	228
198	Temporal Relation Between Ischemic Episodes and Activation of the Coagulation System in Unstable Angina. <i>Circulation</i> , 1996, 93, 2121-2127.	1.6	38

#	ARTICLE	IF	CITATIONS
199	Serum Lipoprotein(a) Level Is Related to Thrombin Generation and Spontaneous Intermittent Coronary Occlusion in Patients With Acute Myocardial Infarction. <i>Circulation</i> , 1996, 94, 2072-2076.	1.6	27
200	Circadian fluctuation of fibrinolytic factors in blood. <i>Developments in Cardiovascular Medicine</i> , 1996, , 185-199.	0.1	0
201	Early spontaneous intermittent myocardial reperfusion during acute myocardial infarction is associated with augmented thrombogenic activity and less myocardial damage. <i>Journal of the American College of Cardiology</i> , 1995, 26, 662-667.	1.2	42
202	Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. <i>American Heart Journal</i> , 1994, 127, 607-612.	1.2	157
203	Thrombin generation after fast or prolonged regimens of tissue-type plasminogen activator. <i>Lancet, The</i> , 1993, 342, 937-938.	6.3	15
204	Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. <i>Journal of the American College of Cardiology</i> , 1993, 21, 1377-1381.	1.2	29
205	High-dose aspirin, thrombin, and coronary angioplasty. <i>Lancet, The</i> , 1993, 341, 1161-1162.	6.3	3
206	Age dependence of ischaemic heart syndromes and the contribution of haemostatic deviations. <i>Fibrinolysis</i> , 1992, 6, 3-4.	0.5	152
207	Effectiveness and safety of a single intravenous Bolus injection of tissue-type plasminogen activator in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1992, 69, 1393-1398.	0.7	8
208	Circadian Variation of Fibrinolytic Activity in Blood. <i>Chronobiology International</i> , 1991, 8, 336-351.	0.9	146
209	Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-1. <i>American Journal of Cardiology</i> , 1991, 68, 1295-1299.	0.7	26
210	Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1990, 65, 1051-1056.	0.7	27
211	Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1990, 16, 1553-1560.	1.2	53
212	Earlier Recanalisation Follows Bolus Administration of Tissue-Plasminogen Activator in Patients with Acute Myocardial Infarction. <i>Clinical Science</i> , 1989, 76, 37P-37P.	0.0	0
213	Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. <i>American Journal of Cardiology</i> , 1988, 62, 635-637.	0.7	432
214	Is it time to introduce anti-inflammatory drugs into secondary cardiovascular prevention: evidence from clinical trials?. <i>Vessel Plus</i> , 0, 2021, .	0.4	2